Management of Metastatic Prostate Cancer After Radical Prostatectomy and Radiation

Introduction to Treatment Paradigms

• The National Comprehensive Cancer Network recommends androgen deprivation therapy (ADT) combined with consideration of systemic intensification with enzalutamide or abiraterone for patients with prostate cancer, elevated PSA, and documented pelvic lymph node disease after both radical prostatectomy and radiation therapy, as this represents metastatic castration-sensitive disease requiring systemic hormonal control 1, 2.

Understanding the Clinical Scenario

• Documented pelvic lymph node disease after prior definitive therapies represents metastatic disease (M1a), requiring systemic rather than additional local therapy 1, 2.

Primary Treatment Recommendation: Systemic Hormonal Therapy

• The National Comprehensive Cancer Network recommends ADT as the Category 1 recommendation for patients with documented positive lymph nodes after radical prostatectomy 1, 4.
• Continuous ADT with LHRH agonist or antagonist is the gold standard for metastatic disease at presentation 2.
• Bilateral orchiectomy remains an alternative for patients preferring surgical castration 2.

Intensified Systemic Therapy Consideration

• Abiraterone acetate plus prednisone combined with ADT is FDA-approved for metastatic castration-naïve prostate cancer and represents another intensification option 2.

Critical Prognostic Assessment

• PSA doubling time (PSADT) <3 months indicates aggressive disease requiring immediate systemic therapy; PSADT <10 months predicts worse outcomes overall 3, 5.
• Testosterone level confirmation of castration-sensitive disease (testosterone ≥150 ng/dL) before initiating ADT 3.

Monitoring and Management During ADT

• PSA every 3 months initially to assess treatment response 3.
• Target PSA ≤4 ng/mL after 7 months of ADT is associated with improved survival in newly diagnosed metastatic disease 2.

Toxicity Surveillance

• Bone density screening for osteoporosis risk, as ADT accelerates bone loss 3, 8.
• Cardiovascular risk assessment given increased risk of metabolic syndrome and cardiovascular events 3, 8.

Treatment Algorithm Summary

• Confirm metastatic disease extent with PSMA-PET/CT and assess PSADT 3, 5.
• Initiate continuous ADT (LHRH agonist/antagonist or orchiectomy) as Category 1 recommendation 1, 2.
• Consider intensification with enzalutamide or abiraterone given metastatic castration-sensitive disease 2.